Get the Stockscreener App
10.82
8.20%
0.82
Amneal Pharmaceuticals Inc stock is traded at $10.82, with a volume of 2.47M.
It is up +8.20% in the last 24 hours and up +8.09% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$10.00
Open:
$10.18
24h Volume:
2.47M
Relative Volume:
1.50
Market Cap:
$3.40B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-15.90
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+2.56%
1M Performance:
+8.09%
6M Performance:
+41.25%
1Y Performance:
+27.74%
1-Day Range:
$10.06
$10.97
1-Week Range:
$9.99
$10.97
52-Week Range:
$6.685
$10.97
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
10.82 | 3.14B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Does Amneal Pharmaceuticals Inc. show high probability of reboundWeekly Profit Analysis & Community Supported Trade Ideas - newser.com
Amneal Pharmaceuticals Hits New 52-Week High of $10.70 - Markets Mojo
Amneal Pharmaceuticals stock hits 52-week high at $10.72 By Investing.com - Investing.com Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Why Amneal (AMRX) Stock Is Up Today - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month High on Strong Earnings - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $10.72 - Investing.com
Truist Raises Price Target on Amneal Pharmaceuticals to $14 From $13, Keeps Buy Rating - MarketScreener
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance - MarketBeat
Will Amneal Pharmaceuticals Inc. stock benefit from automationGap Up & Weekly Chart Analysis and Trade Guides - newser.com
What analyst consensus says on Amneal Pharmaceuticals Inc. stockRate Cut & Safe Capital Growth Stock Tips - newser.com
How high can Amneal Pharmaceuticals Inc. stock goEarnings Trend Report & Precise Swing Trade Entry Alerts - newser.com
Is Amneal Pharmaceuticals Inc. stock ready for a breakoutWeekly Risk Report & Growth-Oriented Investment Plans - newser.com
Published on: 2025-10-31 02:59:36 - newser.com
Amneal Pharmaceuticals (AMRX) Profitability Milestone Tests Investor Optimism on Growth and Valuation - Yahoo Finance
Amneal Pharmaceuticals Reports Strong Q3 2025 Results - TipRanks
Published on: 2025-10-31 00:29:31 - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum play2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Amneal Q3 2025 slides: Revenue up 12% as specialty products gain traction - Investing.com Canada
Amneal: Q3 Earnings Snapshot - Norwalk Hour
How Amneal Pharmaceuticals’ (AMRX) Return to Profitability and Respiratory Product Wins Have Changed Its Investment Story - simplywall.st
Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate - MSN
Earnings call transcript: Amneal Pharma Q3 2025 beats EPS forecast, stock rises - Investing.com
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Amneal Pharmaceuticals, Inc. (AMRX) Q3 FY2025 earnings call transcript - Yahoo Finance
Amneal Pharmaceuticals Outperforms Expectations And Raises Its Full-Year Outlook - Finimize
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Amneal Pharmaceuticals Q3 Adjusted Earnings, Revenue Rise; 2025 EPS Outlook Raised - MarketScreener
Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars - The Globe and Mail
Amneal Pharmaceuticals' Q3 revenue beats estimates, raises guidance for adjusted EBITDA - MarketScreener
(AMRX) Amneal Pharmaceuticals Expects Full Year 2025 Adjusted EPS Range $0.75$0.80, vs. FactSet Est of $0.76 - MarketScreener
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q3 Revenue $784.5M, vs. FactSet Est of $773.9M - MarketScreener
Amneal Pharmaceuticals rise nearly 7% as Q3 results beat expectations By Investing.com - Investing.com Canada
Amneal Reports Third Quarter 2025 Financial Results - The Manila Times
AlphaQuest LLC Acquires 49,305 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Is Amneal Pharmaceuticals Inc. stock resilient to inflationJuly 2025 Highlights & AI Driven Price Predictions - newser.com
Amneal Gets Tentative FDA Approval for Asthma Treatment - MarketScreener
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol - The Manila Times
Amneal (AMRX) receives FDA tentative approval for generic QVAR inhaler; first MDI product - Stock Titan
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Steady Share Price Gains and Growth Initiatives - Yahoo Finance
Will Amneal Pharmaceuticals Inc. stock reach Wall Street targetsWeekly Investment Recap & Reliable Breakout Forecasts - newser.com
Amneal Earnings: What To Look For From AMRX - FinancialContent
Brekiya Migraine Autoinjector Launch Could Be a Game Changer for Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Can Amneal Pharmaceuticals Inc. stock beat market expectations this quarterEarnings Risk Summary & High Accuracy Trade Alerts - Fundação Cultural do Pará
How Amneal Pharmaceuticals Inc. stock compares to industry benchmarksWeekly Trend Report & Free Long-Term Investment Growth Plans - Fundação Cultural do Pará
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):